RoukenBio

Are your preclinical IBD models truly predictive of patient response? 💡 Many IBD programmes still face translational challenges due to the limitations of conventional preclinical models. Discover how RoukenBio's human-relevant ex vivo IBD model uses patient-derived intestinal tissue to generate more clinically relevant insights for therapeutic development. 🔗 Read the scientific resource blog

More human-relevant IBD data. Earlier in development. 🧬 Using patient-derived intestinal tissue, our ex vivo IBD model helps researchers investigate drug response at the site of disease and generate increasingly translational insights. Find out how we're helping advance IBD therapeutic development. ➡️ Read the full article

What if you could evaluate your therapeutic directly in human IBD tissue? 🎯 Our ex vivo IBD model enables drug developers to assess therapeutic candidates in a physiologically relevant microenvironment using patient-derived biopsies. Learn how this approach can support therapeutic testing, mechanistic evaluation and translational research. 👉 Discover more details

IBD isn't driven by a single pathway. Why rely on models that are? 🧫 Crohn's disease and ulcerative colitis involve complex interactions between the immune system and intestinal tissue. See how RoukenBio's ex vivo IBD model helps researchers study drug response within a more comprehensive human tissue environment. 📖 Stay up to date with the latest research into IBD

The translational gap remains one of the biggest challenges in IBD drug development. Traditional models often fail to capture the complex interactions that drive Crohn's disease and ulcerative colitis. 🔬 Explore how our ex vivo IBD model preserves key epithelial, immune and stromal components to support more informed candidate evaluation. 📊 Explore the ex vivo model and data

In this month's scientific newsletter, we're exploring two areas shaping the future of biologics and immunology research: 🧬 FcRn-mediated recycling | Our Director of Innovation, Emilio Cosimo, Ph.D. shares insights into the role of FcRn assays in therapeutic antibody development and optimisation. 🌿 The Next Era of Allergy Drug Development – Associate Director of Allergy, Shatakshi Sood, highlights emerging trends and opportunities driving innovation in allergy therapeutics. If you're developing next-generation biologics, antibodies or allergy therapeutics, these resources offer valuable scientific perspectives and practical insights. 📖 Explore the latest insights in our June Scientific Newsletter and share it with your network. #DrugDevelopment #Biologics #Immunology #FcRn #AllergyResearch #TherapeuticAntibodies